On Monday, Vaxart (NASDAQ: VXRT) released its quarterly financial results. MarketWatch Earnings reported ($0.20) earnings per share, underperforming consensus ($0.16) by ($0.04). As a result of Vaxart’s negative net margin of 7,900.22% and a negative return on equity of 36.68%, it had a negative net margin of 7,900.22%.
In the last 12-month, Vaxart has had a low of $3.11 and a high of $10.33. They have a 50-day SMA of $4.54 and a 200-day SMA of $5.53. The shares have a market cap of $399.44 million, a P/E of -5.45, and a beta of 0.67. Their 12-month low is $3.11, and their 12-month high is $10.33.
Recently, institutional investors purchased and sold Vaxart shares. State Street Corp’s stake in the biotech company increased by 29.6% in the fourth quarter. With an additional 2,554,787 shares purchased last quarter, State Street Corp now owns 11,187,642 shares worth $70,147,000. UBS Group AG increased its Vaxart stake by 1,668.9% in the third quarter. After purchasing 405,804 additional shares last quarter, UBS Group AG now owns 430,119 shares of Vaxart, valued at $3,419,000.
Black Rock Inc. increased its stake in Vaxart shares by 4.4% in the fourth quarter. Black Rock Inc. now owns 8,452,420 shares of the biotechnology company, valued at $52,997,000 after purchasing 357,036 shares.
Morgan Stanley increased its position in Vaxart by 203.5% in the second quarter, now owning 265,935 shares worth $1,992,000 after purchasing another 178,320 shares.
In addition, Dimensional Fund Advisors LP added a new investment in Vaxart during the fourth quarter for an estimated $751,000. Institutional investors and hedge funds own 45.91% of the company.
